(These sessions are not approved for CME credit.)
THURSDAY, NOVEMBER 4, 2021 | 11.00am – 12.30pm
A Treatment Option for Patients with Uncontrolled Moderate-to-Severe Atopic Dermatitis
Symposium supported by Sanofi Genzyme and Regeneron
Faculty: Jonathan Silverberg (Washington, DC, USA)
Learn more about a treatment that may help appropriate patients with uncontrolled moderate-to-severe atopic dermatitis.
Lunch will be provided.
THURSDAY, NOVEMBER 4, 2021 | 12.45am – 02.15pm
New perspectives on pathogenesis in psoriasis
James Krueger (New York City, USA)
Symposium supported by UCB – Union Chimique Belge
THURSDAY, NOVEMBER 4, 2021 | 06.00pm – 07.30pm
Illustrating the GaPPs: Understanding the Challenges in Generalized Pustular Psoriasis
Symposium supported by Boehringer Ingelheim Pharma GmbH & Co. KG
Chair: James Krueger (New York City, USA)
06.00pm-06.20pm |
Generalized Pustular Psoriasis: A Picture of Disease Mechanisms
James Krueger (New York City, USA) |
06.20pm-06.35pm |
Generalized Pustular Psoriasis Flares: A Snapshot of Disease Burden
Jeffrey Crowley (USA) |
06.35pm–06.55pm |
Treatment Challenges and Unmet Needs in Generalized Pustular Psoriasis
Bruce Strober (Connecticut, USA) |
06.55pm–07.15pm |
Coming into Focus: Rationale and Potential for Inhibition of IL-36 in Generalized Pustular Psoriasis
Jeffrey Crowley (California, USA) |
07.15pm–07.30pm |
Live Q&A
James Krueger (New York City, USA) |
FRIDAY, NOVEMBER 5, 2021 | 08.00am – 09.30am
Atopic Dermatitis: The Burden of Disease & a Novel Topical Pathway
Brett King (New Haven, Connecticut, USA)
Symposium supported by Incyte Corporation
FRIDAY, NOVEMBER 5, 2021 | 12.00pm – 01.30pm
Mechanism of disease of atopic dermatitis and hidradenitis suppurativa and the role of inflammatory cytokine pathways
Symposium supported by Janssen Immunology, Pharmaceutical Companies of Johnson & Johnson
12.00pm-12.05pm |
Welcome and introductions
James Krueger (New York City, USA) |
12.05pm-12.20pm |
Broad perspectives in inflammatory cytokines in skin disorders
James Krueger (New York City, USA) |
12.20pm–12.50pm |
Understanding the current status of AD
Emma Guttman (New York, NY, USA) |
12.50pm–01.10pm |
Understanding the current status of HS
James Krueger (New York City, USA) |
01.10pm–01.30pm |
Audience Q&A
Emma Guttman (New York, NY, USA)
James Krueger (New York City, USA) |
FRIDAY, NOVEMBER 5, 2021 | 07.00pm – 08.30pm
Type 2 Inflammation in Skin Barrier and Neuroimmune Axis Dysfunction in Pruritic Dermatoses
Symposium supported by Sanofi Genzyme and Regeneron
07.00pm-07.05pm |
Introduction
Lisa Beck (New York City, USA) |
07.05pm-07.35pm |
The Role of Type 2 Inflammation in Barrier Dysfunction in Pruritic Dermatoses
Lisa Beck (New York City, USA) |
07.35pm–08.05pm |
The Neuroimmune Axis in Itch: Complex Pathophysiology Driving an Important Clinical Symptom
Brian Kim (St. Louis, Missouri, USA) |
08.05pm–08.15pm |
Managing the Clinical Burden of Itch
Lisa Beck (New York City, USA)
Brian Kim (St. Louis, Missouri, USA) |
08.15pm–08.30pm |
Round table discussion
Lisa Beck (New York City, USA)
Brian Kim (St. Louis, Missouri, USA) |
SATURDAY, NOVEMBER 6, 2021 | 08.00am – 09.30am
Not Just Scratching the Surface: A Look into the Role of IL-13 in the Immunopathogenesis of AD
Symposium supported by Eli Lilly and Company
Moderator: Emma Guttman-Yassky (New York City, USA)
08.00am-08.05am |
Welcome and introductions
Emma Guttman-Yassky (New York City, USA) |
08.05am-08.20am |
A Closer Look at IL-13 and its Role in Atopic Dermatitis
Emma Guttman-Yassky (New York City, USA) |
08.20am-08.35am |
A Deep Dive into Type 2 Inflammation and Chronic Itch
Gil Yosipovitch (Miami, Florida, USA) |
08.35am-08.50am |
IL-13 and Neuronal Itch
Ethan Lerner (Boston, Massachusetts, USA) |
08.50am-09.05am |
Cytokine vs. Receptor Targeting: Lessons from Psoriasis
James Krueger (New York City, USA) |
09.05am-09.15am |
Panel Discussion |
09.15am-09.25am |
Audience Q & A |
09.25am-09.30am |
Summary and Concluding Remarks
Emma Guttman-Yassky (New York City, USA) |
SATURDAY, NOVEMBER 6, 2021 | 12.30pm – 02.00pm
New insights into skin phenotypes in atopic dermatitis – are we modifying disease?
Symposium supported by LEO Pharma
Chairs:
- Emma Guttman-Yassky (New York City, USA)
- Kristian Reich (Hamburg, Germany)
12.30pm-12.35pm |
Welcome and setting the scene
Emma Guttman-Yassky (New York City, USA) |
12.35pm-12.50pm |
Can we talk about disease modification in AD?
Kristian Reich (Hamburg, Germany) |
12.50pm-01.05pm |
Shifting the molecular phenotype in AD using targeted treatments
Emma Guttman-Yassky (New York City, USA) |
01.05pm-01.20pm |
The role of acquired versus innate immunity in AD
Kenji Kabashima (Kyoto, Japan) |
01-20pm-01.35pm |
The role of tissue-resident memory T cells, regulatory T cells and the inflammatory phenotype in AD
Patrick Brunner (New York City, USA) |
01.35pm-02.00pm |
Are we modifying disease with emerging treatments?
Panel discussion |
SATURDAY, NOVEMBER 6, 2021 | 04.30pm – 06.00pm
The AD Revolution
Symposium supported by AbbVie
Chair: Emma Guttman-Yassky (New York City, USA)
04.40om-04.50pm |
Overview of the symposium
Objective/Agenda |
04.50pm-05.10pm |
AD care and the HCP/Patient relationship
Shawn Kwatra |
05.10pm-05.30pm |
AD as a multidimensional disease – What we know and what we don’t
Emma Guttman-Yassky (New York City, USA) |
05.30pm-05.50pm |
The AD management future – Pushing the efficacy boundaries
Shawn Kwatra |
05.50pm-06.00pm |
Panel discussion & close |